Literature DB >> 25003812

Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis.

Davide Gatti1, Ombretta Viapiana2, Luca Idolazzi3, Elena Fracassi4, Claudio Ionescu5, Carmela Dartizio6, Sonila Troplini7, Vidya Kunnathully8, Silvano Adami9, Maurizio Rossini10.   

Abstract

The coupling of bone formation to bone resorption during treatment of postmenopausal osteoporosis with antiresorbers might be related to changes in Wnt/b-catenin signaling. We compared the effects of two bisphosphonate treatments on two Wnt-inhibitors Sclerostin (SOST) and Dickkopf-related protein 1 (DKK1). The study population included 74 women with postmenopausal osteoporosis participating simultaneously in two multicenter, placebo controlled trials. The patients were randomized to: intramuscular clodronate 100mg/week (CLO) (N=36), and yearly intravenous therapy with 5mg zoledronate (ZOL) (N=18) and placebo (N=20). Bone turnover markers (intact N-propeptide of type I collagen [P1NP], C-terminal telopeptide of type I collagen [CTX]) remained unchanged in the placebo group while they significantly decreased during treatment with the two bisphosphonates, versus both placebo and baseline. In CLO treated patients serum DKK1 remained stable over the entire period of observation while serum SOST levels increased significantly after 12months of treatment both versus placebo group (p<0,005), baseline (p<0,001) and ZOL treated group. In the ZOL group, DKK1 levels increased significantly within one month and for the following 6months and it fell back to baseline values at 12months. The second ZOL infusion was again associated with an increase in DKK1 a month later, although to a lesser extent. In conclusion, in this study we have found that the treatment of postmenopausal osteoporosis with intermittent yearly ZOL is associated with transient and declining increases in DKK1 while continuous treatment with CLO, results in a late increase in serum SOST. These preliminary results and further ad hoc studies might contribute to shed light on our understanding of the bone coupling effects taking place during treatment of osteoporosis with different anti-resorbers or with different treatment regimens.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clodronate; DKK-1; Sclerostin; Zoledronate

Mesh:

Substances:

Year:  2014        PMID: 25003812     DOI: 10.1016/j.bone.2014.06.037

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  7 in total

1.  Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion.

Authors:  Athanasios D Anastasilakis; Stergios A Polyzos; Maria P Yavropoulou; Charikleia Ntenti; Stylianos Mandanas; Polyzois Makras
Journal:  Endocrine       Date:  2021-03-02       Impact factor: 3.633

Review 2.  The Utility of Biomarkers in Osteoporosis Management.

Authors:  Patrick Garnero
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

3.  Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone.

Authors:  Luca Idolazzi; Angelo Fassio; Gaia Tripi; Vania Braga; Ombretta Viapiana; Giovanni Adami; Maurizio Rossini; Davide Gatti
Journal:  Clin Rheumatol       Date:  2017-01-05       Impact factor: 2.980

4.  Microglial Depletion with Clodronate Liposomes Increases Proinflammatory Cytokine Levels, Induces Astrocyte Activation, and Damages Blood Vessel Integrity.

Authors:  Xiaoning Han; Qian Li; Xi Lan; Leena El-Mufti; Honglei Ren; Jian Wang
Journal:  Mol Neurobiol       Date:  2019-02-08       Impact factor: 5.590

Review 5.  Osteopontin: Relation between Adipose Tissue and Bone Homeostasis.

Authors:  Carolina De Fusco; Antonietta Messina; Vincenzo Monda; Emanuela Viggiano; Fiorenzo Moscatelli; Anna Valenzano; Teresa Esposito; Chieffi Sergio; Giuseppe Cibelli; Marcellino Monda; Giovanni Messina
Journal:  Stem Cells Int       Date:  2017-01-17       Impact factor: 5.443

Review 6.  Aptamers for Proteins Associated with Rheumatic Diseases: Progress, Challenges, and Prospects of Diagnostic and Therapeutic Applications.

Authors:  Elizaveta A Shatunova; Maksim A Korolev; Vitaly O Omelchenko; Yuliya D Kurochkina; Anna S Davydova; Alya G Venyaminova; Mariya A Vorobyeva
Journal:  Biomedicines       Date:  2020-11-22

7.  Relationship Between Changes in Serum Levels of Intact Parathyroid Hormone and Sclerostin After a Single Dose of Zoledronic Acid: Results of a Phase 1 Pharmacokinetic Study.

Authors:  Tatsuhiko Kuroda; Masataka Shiraki; Toshitaka Nakamura; Hiroaki Suzuki; Kazuki Hiraishi; Toshitsugu Sugimoto; Satoshi Tanaka
Journal:  Calcif Tissue Int       Date:  2021-08-24       Impact factor: 4.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.